Result card

  • CUR6: What aspects of the consequences / burden of disease are targeted by the intravenous immunoglobulin (IVIG) therapy?
English

What aspects of the consequences / burden of disease are targeted by the intravenous immunoglobulin (IVIG) therapy?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo

Internal reviewers: Kristian Lampe

Intravenous immunoglobulins (IVIG) are expected to have potentially beneficial effects on the pathogenetic process of Alzheimer’s disease by stabilizing cognitive functioning in patients with mild-to-moderate Alzheimer’s disease {20} {46}. The benefits of IVIG in AD are believed to be related to fact that they contain both anti- tau and anti-Aβ natural antibodies and can help in reducing the misfolding, aggregation and deposition of amyloid-β, and deposition of misfolded tau protein in neurofibrillary tangles {Kayed}. The neuroprotective mechanisms of IVIG are not well known {82}.

If mild cognitive impartment would be identified early this would allow earlier treatment to slow progression of AD or even prevent it. Early interventions are likely to be more effective than if the disease is already advantaged. Slowing the progression of AD with IVIG or other therapies could have major impact on the need for care and burden of the disease.

At the moment it is not possible to assess impact of IVIG on AD mortality or other impacts on patients since we lack clinical studies.

A problem can arise in the supply of IVIG. IVIG is prepared from the plasma immunoglobulins of over 10 000 donors and the processing of plasma into IVIG takes about 9 months. IVIG treatment is therefore expensive. Supply could become a major problem if IVIG products would be used for AD unless new manufacturing processes are developed. {46}.

Critical
Completely
Migliore A et al. Result Card CUR6 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References